Suzetrigine for Acute Pain
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
How does the drug Suzetrigine differ from other treatments for acute pain?
Suzetrigine may be unique in its approach to treating acute pain by potentially combining mechanisms similar to those of suprofen, which inhibits prostaglandin biosynthesis, and lamotrigine, which has shown effectiveness in reducing pain through neuronal sensitization. This combination could offer a novel way to manage pain without the side effects associated with opioids or traditional non-steroidal anti-inflammatory drugs.12345
What is the purpose of this trial?
The purpose of this study to evaluate the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.
Eligibility Criteria
This trial is for individuals with a BMI of 18.0 to 40.0 kg/m^2 who are scheduled for aesthetic or reconstructive surgery, normally treated with opioids post-surgery. It's not specified who can't join the trial.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Suzetrigine (SUZ) as part of multimodal therapy for up to 14 days or until pain resolves
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Suzetrigine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vertex Pharmaceuticals Incorporated
Lead Sponsor
Dr. David Altshuler
Vertex Pharmaceuticals Incorporated
Chief Medical Officer since 2020
MD, PhD
Dr. Reshma Kewalramani
Vertex Pharmaceuticals Incorporated
Chief Executive Officer since 2020
MD, trained in internal medicine and nephrology